跳至主要内容
临床试验/NCT02949167
NCT02949167Unknown不适用

MyHealth: Nurse-led Compared to Physician-led Breast Cancer Follow-up: A Randomized Controlled Trial

Danish Cancer Society2 个研究点 分布在 1 个国家目标入组 503 人开始时间: 2016年11月最近更新:
适应症

试验速览

阶段
不适用
入组人数
503
试验地点
2
主要终点
Changes in breast cancer specific symptom burden (TOI-PFB)

研究概览

简要总结

Approximately 24,000 women attend a follow-up care program after end of primary treatment for breast cancer (BC) in Denmark. There is no well-conducted, larger randomized controlled trials (RCT) outlining a gold standard for follow-up programs ensuring early detection of recurrence, good management of symptoms and cost-effectiveness. The primary aim of this randomised, controlled trial is to test whether a nurse-led individually tailored symptom management program (MyHealth) will significantly reduce reported symptoms among BC patients following primary treatment compared to physician-led scheduled follow-up. Secondary, the investigators will examine patient activation (self-management), anxiety, depression, fear of recurrence, work ability, time to recurrence, overall survival, health behavior changes, health care utilization and financial costs in the two arms.

The MyHealth program provides patients with a nurse-led education focusing on management of symptoms, an electronic platform to report symptoms to the nurses and support in symptom management and navigation of patients to appropriate health care services.

详细描述

During an 18-month period, 494 primary BC patients will be recruited from the Departments of Oncology at Naestved and Roskilde Hospital. The women will be enrolled in the study following completion of primary treatment. Participants are randomized 1:1 to the intervention (Nurse-led follow up) or control group (physician-led follow-up) and followed for 5 years. No matter group assignment, all women will follow the national mammography screening programs.

Patients who accept to participate are asked to invite a close relative, preferably partners, to participate in the study. Patients, who do not want to participate in the randomization will be asked if they are willing to participate in the study by filling out two questionnaires. Patients who decline to participate in the MyHealth study will be enrolled in the standard follow-up.

The investigators will collect data using questionnaires, clinical databases, and national registers before intervention and for 5 years after inclusion both in the control and intervention arm. Questionnaires from validated scales are used to measure primary and secondary outcomes in both groups whereas Patient Reported Outcomes (PRO) are only collected in the intervention group. Patients who experiences relapse during the MyHealth intervention will not be asked to fill in the remaining outcome questionnaires or PROs since they quit the follow-up program in favor of treatment for recurrent disease.

During follow-up, the patient will consult the nurse or the project physician if PROs reveal a need, or if the patient require a consultation. In order to ensure that treatment of symptoms and referral to other health professionals will meet clinical guidelines the nurses are instructed to follow a detailed response algorithm, which is developed by the project physician in collaboration with experienced oncologists.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Complete remission following primary treatment for loco-regional BC (stage I-II) - No confirmed genetic predisposition to BC
  • Female gender
  • Performance status ≤3
  • Read, understand and speak Danish
  • No severe cognitive problems
  • No severe psychiatric disease requiring treatment or any substance abuse.

排除标准

  • Genetic predisposition for BC
  • Patient younger than 40 years of age at diagnosis
  • Control after recurrent breast cancer
  • Other active cancer except non-melanoma skin cancer
  • Severe cognitive problems or dementia
  • Severe psychiatric disease requiring treatment, e.g. schizophrenia, alcohol or narcotic dependence

结局指标

主要结局

Changes in breast cancer specific symptom burden (TOI-PFB)

时间窗: at inclusion, 6 months,12 months, 24 months, 36 months and 60 months

Trial Outcome Index-Physical/Functional/Breast (TOI-PFB) score of the Functional Assessment of Cancer Therapy -Breast (FACT-B) Domains: Physical well-being, Functional wellbeing,BC symptoms

次要结局

  • Changes in Depression(at inclusion, 6 months,12 months, 24 months, 36 months and 60 months)
  • Changes in breast cancer specific symptom burden(at inclusion, 6 months,12 months, 24 months, 36 months and 60 months)
  • Changes in self-management(at inclusion, 6 months,12 months, 24 months, 36 months and 60 months)
  • Changes in knowledge, skill, and confidence for self-management(at inclusion, 6 months,12 months, 24 months, 36 months and 60 months)
  • Changes in anxiety(at inclusion, 6 months,12 months, 24 months, 36 months and 60 months)
  • Changes in quality-adjusted life year (QALY)(at inclusion, 6 months,12 months, 24 months, 36 months and 60 months)
  • Changes in fear of recurrence(at inclusion, 6 months,12 months, 24 months, 36 months and 60 months)
  • Changes in work ability(at inclusion, 6 months,12 months, 24 months, 36 months and 60 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Christoffer Johansen

Professor

Danish Cancer Society

研究点 (2)

Loading locations...

相似试验